475results about How to "Suitable for clinical application" patented technology

The invention relates to an oxiracetam freeze-drying preparation for injection and a preparation method thereof, belonging to the technical field of medicines. The freeze-drying preparation is a crystal form compound formed by oxiracetam, D-sorbitol and mannitol in a weight ratio of 1: (0.2-0.25): (0.05-0.1). The oxiracetam freeze-drying preparation has the beneficial effects that the production cycle is shortened by about 20 hours, the rate of finished products is increased by above 99%, the phenomena such as the upward shifting and the eruption of the product are avoided, medicine molecules are constrained in crystal lattices, the water content is extremely low and can be controlled below 0.1%, the preparation is difficult to degrade and has relatively good stability, the period of validity is up to 36 months, the impurity content is greatly reduced, the single maximum impurity is less than 0.1%, and the total impurities are less than 0.5%; no organic solvents are involved in the production process, the energy consumption and the cost are substantially reduced, and the technology has environmentally-friendly effect and is suitable for large-scale industrialization production. Compared with the prior art, the oxiracetam freeze-drying preparation provided by the invention has obviously improved curative effect and is suitable for clinical application.

The invention provides a pharmaceutical composition for treating embolism and a preparation method thereof, the pharmaceutical composition comprises a hydroxyl-contained biocompatible polymer materialand a monomer containing unsaturated double bonds and anion groups, as well as a polymer generated by polymerization reaction of an optional vinyl monomer, wherein the polymerization is initiated through free radicles, and bleomycin or pingyangmycin is combined on the anion groups of the generated polymer. The preparation method combines the bleomycin or the pingyangmycin on a carrier of the polymer, thereby being capable of fully playing the dual effects of an anti-tumor antibiotic and a hardening agent owned by the bleomycin or the pingyangmycin during the embolism treatment. The anion partof the polymer can be properly combined with the bleomycin or the pingyangmycin which is rich in amino groups, thereby not only realizing the higher drug loading, but also leading the drug in an emboliaztion agent to be exchanged by cation in human body, and further realizing the slow release. In addition, the embolic carrier of the polymer has the advantages of simple prepration technology andlow cost, thereby being applicable to large-scale industrial production.

The invention discloses a method for preparing a block polymer micelle freeze-drying preparation carrying docetaxel, which uses a PEO-PPO-PEO block polymer as a micelle carrier to wrap the docetaxel inside the micelle and comprises the following steps: (1) dissolving the carrier and the docetaxel into an organic solvent to make the PEO-PPO-PEO block polymer and the docetaxel fully dissolved in the organic solvent, and then preparing aqueous solution of the docetaxel micelle by using the PEO-PPO-PEO block polymer as the carrier; and (2) adding a freeze-drying protective agent into the aqueous solution of the PEO-PPO-PEO block polymer carrying micelle, and filtering, sterilizing and freeze-drying the mixture to obtain freeze-drying preparation of the carrier micelle system. The block polymer micelle freeze-drying preparation carrying the docetaxel can increase the dissolubility, metabolic stability and in vivo circulation time of the docetaxel, reduce the toxicity and improve the bioavailability, and is more suitable for clinical application.

The invention provides a method for in vitro induction and amplification of a human antigen nonspecific regulatory T cell. A human peripheral blood CD4<+> T cell with an abundant source is separated, and a CD4<+>CD25<-> T cell is induced and amplified into a CD4<+>CD25<+>CD127<dim> antigen nonspecific regulatory T cell with high purity and high regulation efficiency within a short period through a simple induction method meeting the Clinical Good Manufacturing Practice (GMP). An enough therapeutic dose of Treg can be obtained through induced cultivation of a week (6-7d), the phenotype and regulation function of the induced Treg are stable, furthermore, the incidence rate of events, such as cell activity reduction and microbial contamination due to long-term culture in vitro is greatly reduced, and the quality control method is specific and fast and is very suitable for clinical application.

The invention discloses a traditional Chinese medicine composition for treating allergic rhinitis, comprising the following crude medicines in parts by weight: 28-32 parts of honeysuckle, 28-32 parts of baical skullcap root, 28-32 parts of paniculate swallowwort root, 13-17 parts of xanthium, 13-17 parts of magnolia flower, 7-11 parts of asarum, 7-11 parts of mint, 13-17 parts of angelica, 13-17 parts of centipeda minima, 22-26 parts of chuanxiong rhizome and 16-20 parts of borneol. The preparation method comprises the steps of crushing all components, screening with a sieve of 200 meshes and mixing evenly. When used for treatment, the medicament provided by the invention is put into a medicine bag made of non-woven fabric, then the medicine bag is sown on the inner surface of a disposable mask, and a patient wears the mask and aligns the medicine bag with the nostrils. A course of treatment lasts for 5 days, and generally allergic rhinitis can be cured by two courses of treatment. The medicament provided by the invention is directly inhaled and has the advantages of quick effect taking, convenience in use, safety, reliability, no toxic side effect, low cost and the like.

The invention discloses freeze drying composition of atracurium. The composition adopts atracurium or its pharmaceutically acceptable salt or optical isomer as active ingredient, and also comprises sugar and organic acid. The invention also discloses a method for preparing the composition. The inventive composition has good water-solubility and good storing stability, low stimulation to blood vessel, and high safety; is suitable for clinical application.

The invention discloses recombinant proserum/growth hormone fusion protein, a preparation and purification method of the recombinant fusion protein, and the use of the recombinant fusion protein to preparation of medicines for treating children dwarfism. The amino acid sequence of the recombinant proserum/growth hormone fusion protein is SEQID NO.1, and the nucleotide sequence of the recombinant proserum/growth hormone fusion protein is SEQID NO.2. According to a preparation technology of the recombinant proserum/growth hormone fusion protein disclosed by the invention, yeast engineering bacteria are constructed and expressed, so that high-density expression recombinant fusion protein is obtained; and through a purification technology, the recombinant proserum/growth hormone fusion proteinwhich can be used clinically is obtained. The recombinant proserum/growth hormone fusion protein obtained by the preparation and purification method adopts a creative medicine structure for treatingthe children dwarfism, has long residual action that administration can be performed once every two weeks, is more suitable for children medication demands, and has more excellent treatment effects, less administration frequency and lower production cost.

The invention discloses a large ovarian tissue vitrification freezing carrier. The carrier consists of a carrier inner core and an outer sleeve, wherein the carrier inner core is in threaded connection with the outer sleeve, maintaining high airtightness and preventing cross infection of the ovarian tissue; meanwhile, the user operation is also facilitated; the carrier inner core consists of a handheld part, a cap part, a support part and a bearing part sequentially from top to bottom; the bearing part is clamped and fixed by the support part; when in use, a large ovarian tissue is put on an end part of the bearing part, away from the support part; the end part is a large ovarian tissue loading area; experiments prove that by using the carrier disclosed by the invention, the permeation efficiency of a refrigerant is improved; moreover, the operation is simple, the price is low, batch storage of large ovarian tissues is convenient, and the carrier is suitable for promotion and application.

The invention belongs to the technical field of tissue engineering, and discloses artificial skin and a preparation method thereof. The artificial skin comprises epithelial cells, dermal cells and a biological bracket material. The preparation method comprises the following steps: compounding the dermal cells into the biological bracket material; inoculating the epithelial cells on the surfaces of the dermal cells; carrying out cultivation. As the artificial skin comprises a corium layer, an epidermal layer and active cells, and the epidermal layer comprises cuticle, the artificial skin is similar to normal skin, human skin with complete functions can be regenerated after the transplanting of the artificial skin, and the regenerated skin comprises skin appurtenant organs such as hair and sebaceous glands. Therefore, the artificial skin can be used for treating skin defect caused by inflammation, ulcer, burning and scalding, and also can be used for preparation of skin models used for disease researches, medicine testing and screening, cosmetic testing, or the like.

The invention discloses novel radioactive 18F labeled amino acid derivatives, which are used in research on tumor positron emission tomography (PET) imaging. The derivatives are characterized in that one end of the derivatives is provided with F substituted alkoxy benzoyl structure, and the other end of the derivatives is provided with alpha-amino acid structure; substituent R1 is positioned on an alpha site of carboxyl group and is hydrogen, methyl group, ethyl group, propyl group, isopropyl group, butyl group, methylthio-ethyl group, methyl acetate group or propionate carbomethoxy group; R2 is methoxy group; and n is a number between 1 and 5. The R1 is hydrogen, methyl group, ethyl group, propyl group, isopropyl group, butyl group, methylthio-ethyl group, methyl acetate group or propionate carbomethoxy group; the R2 is hydrogen; and the n is a number between 1 and 5. Compounds improve fat solubility. Different amino acid structures are introduced into the structure, and F in the structure is 19F and 18F. Compared with the prior art, the 18F labeled amino acid derivatives provided by the invention have better discrimination degree of biological distribution, the potential of being used as a tumor imaging agent (particularly a brain tumor imaging agent), as well as the characteristics of simple preparation and high labeling rate. The R1 is hydrogen, methyl group, ethyl group, propyl group, isopropyl group, butyl group, methylthio-ethyl group, methyl acetate group or propionate carbomethoxy group; the R2 is methoxy group; and the n is a number between 1 and 5. The R1 is hydrogen, methyl group, ethyl group, propyl group, isopropyl group, butyl group, methylthio-ethyl group, methyl acetate group or propionate carbomethoxy group; the R2 is hydrogen; and the n is a number between 1 and 5.

The invention belongs to the field of chemical pharmacy and in particular relates to a cisatracurium besilate composition for injection and a preparation method and application thereof. The cisatracurium besilate composition for injection comprises cisatracurium besilate, sodium chloride, glucose and a pH regulator, wherein cisatracurium besilate takes cisatracurium as an active ingredient, and cisatracurium, sodium chloride and glucose are combined according to a certain ratio. The cisatracurium besilate composition for injection disclosed by the invention is simple in composition, convenient to operate, simple in freeze-drying process, controllable in quality, low in content of product related substances, high in reproducibility and convenient to popularize and utilize.

The invention relates to a preparation method of a magnesium-hydroxyapatite/polylactic acid composite molding material. The preparation method comprises the following steps that: PLA is dissolved in organic solvent, the prepared hydroxyapatite solution is directly fully mixed with the organic solvent dissolved with polylactic acid, then HA/PVA composite is prepared by means of volatilizing and drying the solvent, the composite is dissolved in the organic solvent and is added with M9 powdery particles for intensive mixing, then the magnesium-hydroxyapatite/polylactic acid composite material isobtained by volatilizing and drying the solvent, and finally the magnesium-hydroxyapatite/polylactic acid composite material is molded by injection molding or mold pressing technology. The preparation method provided by the invention has the advantages that the M9-HA/PLA composite material is prepared by the solution blending technology, the dispersible uniformity and the biocompatibility of magnesium and hydroxyapatite in the polylactic acid are improved, the loss of molecular weight of polylactic acid in the preparation process is reduced, the balanced dynamics performance and the degradation rate of the material are guaranteed, and the preparation method is much more applicable to clinical bone repair; in addition, the preparation method is simple in technology and low in cost and is much more suitable for productization production.